Wilson Sonsini Goodrich & Rosati advised Boundless Bio on IP matters related to the transaction. Boundless Bio, a clinical-stage, next-generation precision oncology company developing innovative therapeutics...
Boundless Bio’s $100 Million Series C Financing
Janux Therapeutics’ $193.8 Million IPO
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics, Inc. on the deal, while Latham & Watkins LLP represented the underwriters. Janux Therapeutics, Inc., a biopharmaceutical company...